FDA: breakthrough therapy designation for Avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, in metastatic Merkel cell carcinoma
The FDA ( Food and Drug Administration ) has granted Avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Breakthrough Therapy designation for the treatment of patients with m ...
read article